Compile Data Set for Download or QSAR
Report error Found 98 Enz. Inhib. hit(s) with all data for entry = 8790
TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419858(US10464927, Compound I-6)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419859(US10464927, Compound I-7)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419859(US10464927, Compound I-7)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419856(US10464927, Compound I-4)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419857(US10464927, Compound I-5)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419857(US10464927, Compound I-5)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419854(US10464927, Compound I-2)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419854(US10464927, Compound I-2)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419855(US10464927, Compound I-3)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419855(US10464927, Compound I-3)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM6309(8-cyclopentyl-6-acetyl-5-methyl-2-{[5-(piperazin-1...)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM6309(8-cyclopentyl-6-acetyl-5-methyl-2-{[5-(piperazin-1...)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419853(US10464927, Compound I-1)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419853(US10464927, Compound I-1)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419866(US10464927, Compound I-14)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419866(US10464927, Compound I-14)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419864(US10464927, Compound I-12)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419864(US10464927, Compound I-12)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419865(US10464927, Compound I-13)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419862(US10464927, Compound I-10)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419863(US10464927, Compound I-11)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419860(US10464927, Compound I-8)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419874(US10464927, Compound I-22)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419874(US10464927, Compound I-22)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419875(US10464927, Compound I-23)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419875(US10464927, Compound I-23)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419872(US10464927, Compound I-20)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419872(US10464927, Compound I-20)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419873(US10464927, Compound I-21)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419870(US10464927, Compound I-18)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419870(US10464927, Compound I-18)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419871(US10464927, Compound I-19)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419868(US10464927, Compound I-16)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419868(US10464927, Compound I-16)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419869(US10464927, Compound I-17)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419882(US10464927, Compound I-30)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419883(US10464927, Compound I-31)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419883(US10464927, Compound I-31)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419880(US10464927, Compound I-28)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419881(US10464927, Compound I-29)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419881(US10464927, Compound I-29)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419878(US10464927, Compound I-26)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419879(US10464927, Compound I-27)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419879(US10464927, Compound I-27)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419876(US10464927, Compound I-24)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419876(US10464927, Compound I-24)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419877(US10464927, Compound I-25)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419877(US10464927, Compound I-25)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419890(US10464927, Compound I-38)
Affinity DataIC50: 20nMAssay Description:CDK4: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Xunhe Pharmaceutical Technology

US Patent
LigandPNGBDBM419890(US10464927, Compound I-38)
Affinity DataIC50: 20nMAssay Description:CDK6: The test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl2, 2 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
US Patent

Displayed 1 to 50 (of 98 total ) | Next | Last >>
Jump to: